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Abstract: The continued emergence and re-emergence of pathogens represent an ongoing, 
sometimes  major,  threat  to  populations.  Hantaviruses  (family  Bunyaviridae)  and  their 
associated human diseases were considered to be confined to Eurasia, but the occurrence of 
an outbreak in 1993–94 in the southwestern United States led to a great increase in their 
study  among  virologists  worldwide.  Well  over  40  hantaviral  genotypes  have  been 
described, the large majority since 1993, and nearly half of them pathogenic for humans. 
Hantaviruses  cause  persistent  infections  in  their  reservoir  hosts,  and  in  the  Americas, 
human disease is manifest as a cardiopulmonary compromise, hantavirus cardiopulmonary 
syndrome  (HCPS),  with  case-fatality  ratios,  for  the  most  common  viral  serotypes,  
between  30%  and  40%.  Habitat  disturbance  and  larger-scale  ecological  disturbances, 
perhaps  including  climate  change,  are  among  the  factors  that  may  have  increased  the 
human caseload of HCPS between 1993 and the present. We consider here the features that 
influence the structure of host population dynamics that may lead to viral outbreaks, as 
well as the macromolecular determinants of hantaviruses that have been regarded as having 
potential contribution to pathogenicity. 
Keywords:  hantavirus;  hantavirus  cardiopulmonary  syndrome;  emergence;  pathology; 
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1. Introduction 
Emerging pathogens cause new or previously unrecognized diseases, and among them, emerging 
zoonotic diseases are a major concern among scientists studying infectious diseases at different spatial 
and  temporal  scales  [1,2].  Changes  in  biotic  and  abiotic  conditions  may  alter  population  disease 
dynamics and lead to the emergence of zoonotic infections [3–6]. During the last decades, several 
outbreaks of emerging and re-emerging viral pathogens have occurred, affecting both purely-local and 
worldwide/pandemic  involvement  of  human  populations.  Among  the  conspicuous  examples  are 
influenza A, Ebola virus, hepatitis C virus, severe adult respiratory distress (SARS), coronavirus, and 
human immunodeficiency virus, which challenge prevention and control measures of public health 
systems [7]. In the Americas, the recent outbreak of pandemic influenza A subtype H1N1 became a 
major target for control due to its rapid spread, and uncertainties in virulence and transmissibility, yet 
vaccine  availability  was  limited  when  significant  activity  occurred  in  advance  of  the  traditional 
influenza season [8]. However, in the last century outbreaks of several viral-related diseases have 
emerged or re-emerged involving arenaviruses and dengue viruses, and more recently, hantaviruses, 
and  the  expansion  of  the  geographic  range  of  West  Nile  virus.  Among  zoonotic  diseases,  small 
mammals are hosts of several pathogenic RNA viruses, especially Arenaviridae and Bunyaviridae: 
Hantavirus [9–11]. 
Hantavirus infections became a concern in the Americas after the description of an outbreak of 
acute  respiratory  distress  occurred  in  the  Four  Corners  area  in  1993  [12].  The  newly  recognized 
disease,  hantavirus  cardiopulmonary  syndrome,  HCPS  (or  hantavirus  pulmonary  syndrome),  was 
linked to infection by the newly-discovered Sin Nombre virus (SNV), and the rodent Peromyscus 
maniculatus (deer mouse) was identified as the reservoir [13]. However, hantavirus infections have a 
much longer history. A review of ancient Chinese writings, dating back to approximately 960 AD, 
revealed  descriptions  closely  resembling  hemorrhagic  fever  with  renal  syndrome  (HFRS),  the 
syndrome caused by Old World hantaviruses [14]. During the twentieth century, cases of acute febrile 
disease with renal compromise were described from several Eurasian countries and Japan, often in 
association with military engagements [15]. HFRS as a distinct syndrome, however, was first brought 
to  the  attention  of  western  medicine  in  association  with an  outbreak  that  occurred  among  United 
Nations troops during the Korean conflict between 1951 and 1954, where more than 3,200 soldiers 
were afflicted [16]. It took more than two decades until the etiologic agent, Hantaan virus (HTNV), 
was isolated  from the striped  field mouse  Apodemus agrarius, detected in  part by the binding of 
antibodies from patient serum samples to the lung tissues of healthy, wild-caught field mice [17,18]. 
The virus was later found to represent the type species of a new genus  Hantavirus of the family 
Bunyaviridae, although it was later apparent that the first hantavirus to be isolated was the shrew-borne 
Thottapalayam virus [19]. The categorization of hantaviruses as belonging to the family Bunyaviridae 
is due in part to the consistent presence of three RNA genomes that are circularized in vivo as a result 
of the presence of terminal complementary nucleotides that help fold the genome into a ―hairpin‖ 
morphology,  first  described  for  the  Uukuniemi  phlebovirus  [19,20].  Table  1  is  a  list  of  the 
predominant,  serologically  distinct  pathogenic  hantaviruses.  Many  other  named  genotypes  are 
described, but such other pathogenic forms are generally closely related to Andes or, in some cases, 
Sin Nombre virus. Viruses 2010, 2                         
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Table 1. Major human-pathogenic hantaviruses.  
  Virus strain  Acronym 
Geographic 
Distribution 
Host  Pathology 
Case-
fatality 
ratio 
(%) 
New 
World 
Sin Nombre  SNV  North America 
Peromyscus 
maniculatus 
HCPS  –35 
  Choclo  CHOV  Panamá 
Oligoryzomys 
fulvescens 
HCPS  ~21 
  Andes  ANDV  Argentina, Chile 
Oligoryzomys 
longicaudatus 
HCPS  35 
  Laguna Negra  LANV 
Argentina, Bolivia, 
Paraguay, 
Calomys laucha, 
C. callosus 
HCPS  5–15 
Old 
World 
Hantaan  HTNV 
China, Korea, 
Russia 
Apodemus 
agrarius 
HFRS  5–0 
  Seoul  SEOV  Worldwide 
Rattus rattus,  
R. norvegicus 
HFRS  1–2 
  Puumala  PUUV 
Scandinavia, 
western Europe, 
Russia 
Myodes glareolus  HFRS/NE  0.1–0.4 
 
Dobrava-
Belgrade 
DOBV  Balkans 
Apodemus 
flavicollis 
HFRS  5–10 
HCPS: Hantavirus cardiopulmonary syndrome; HFRS: Hemorrhagic fever with renal syndrome; 
NE: Nephropathia epidemica 
 
Hantavirus  discovery  continues  at  a  rapid  pace.  After  the  identification  of  SNV  in  1993, 
approximately 43 genotypes have been reported in the Americas alone (Figure 1), with 20 of those 
associated with clinical cases of HCPS. Most hantaviruses worldwide have been identified in murid or 
cricetid rodents of the subfamilies Murinae, Arvicolinae, Neotominae, and Sigmodontinae as their 
main reservoir, but the discovery of hantaviruses in insectivores (Soricidae, Talpidae) on at least three 
continents [21,22] shows that the genetic diversity of hantaviruses is far higher than expected.  
2. Molecular Features and Cell Interactions  
Member viruses of the family Bunyaviridae, including those of the genus Hantavirus are spherical, 
enveloped  viruses  of  100–200  nm  diameter  with  a  tripartite  helical  nucleocapsid.  The  hantavirus 
genome is composed of three negative sense single stranded RNA segments: (i) The large (L) segment 
of approximately 6,500 nucleotides (nt) encodes a RNA-dependent RNA polymerase of ~2,160 amino 
acids (aa); (ii) The middle (M) segment is 3,700-nt long, and encodes the envelope glycoprotein 
precursor (GPC), which is processed into two transmembrane glycoproteins, Gn (652 aa, formerly 
―G1‖)  and  Gc  (488  aa,  previously  ―G2‖)  through  a  cotranslational  proteolytic  mechanism  in  the 
endoplasmic reticulum [23–26]; (iii) The small (S) segment length varies from ~1,700 to 2,100 nt, and 
encodes  an  RNA-binding  nucleocapsid  (N)  protein  that  ranges  between  428  and  436-aa  for 
hantaviruses.Viruses 2010, 2                         
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Figure 1. Map of hantavirus genotypes in the Americas reported to be non-pathogenic or of unknown pathogenicity (blue) and pathogenic 
(red) for humans. Hantaviruses reported in Soricomorpha (shrews and moles) are underlined. 
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2.1. Envelope Glycoproteins 
During  virus  maturation,  the  precursor  form  GPC  is  processed  using  a  membrane-bound 
protease into Gn and Gc, a cleavage that occurs, and appears to be signaled, after the conserved 
peptide signal WAASA at the C-terminal of Gn [24]. Although the two proteins can be expressed 
independently through transfection, they can be retained in the wrong cellular compartment (ER or 
aggresome); they thus must be co-expressed to allow them stability so that the two can be assembled 
correctly in the Golgi [25,27–29]. 
A  number  of  activities  and  properties  have  been  identified  for  the  hantavirus  envelope 
glycoproteins, including some features that are suspected to be involved in the pathogenicity of 
the  disease-causing  serotypes,  a  possibility  that  has  engendered  experimental  attention.  The 
glycoproteins are the known or presumed ligands for at least two distinct cellular receptors, the 
3 integrin chain and decay accelerating factor, or DAF [30,31]; with gC1qR/p32 also identified as 
another potential entry receptor [32]. Comparisons with the tick-borne encephalitis virus E protein, 
led Tischler et al. to consider the Gc glycoprotein as a potential class II fusion protein, perhaps imparting 
fusion activity to the virion, and this hypothesis has gained support in other studies [33,34]. 
Additional activities have been identified with, or claimed to be related to, Gn. For many of these 
studies,  an  underlying  premise  has  held  that  there  are  differences  between  the  glycoproteins  of 
―pathogenic‖ hantaviruses relative to viruses in the genus that are dubbed to be ―non-pathogenic‖. 
While it is true that it has not yet been possible to link Prospect Hill virus (PHV) to human disease, the 
absence  of evidence  for  its  pathogenicity  should  perhaps  not  be  equated  with  the  evidence  of  its 
absence.  One  might  only  consider  that  the  level  of  disease  (e.g.,  lethargy,  fever,  proteinuria,  and 
azotemia) associated with infection of nonhuman primates by PHV is not significantly different from 
that  recorded  for  nonhuman  primate  models  using  the  known-pathogen  Puumala  virus 
(PUUV) [35,36]. For the purpose of this discussion we will presume that apathogenic hantaviruses are 
indeed apathogenic. 
While  some  studies  have  suggested  that  Gn  glycoproteins  are  directed  more  rapidly  into  the 
ubiquitin-proteosome pathway than are apathogenic forms, others have interpreted differences in the 
handling  of  Gn  glycoproteins  across  hantavirus  species  by  the  ubiquitin-proteosomal  system  as 
independent  of  pathogenicity  [37–39].  Some  investigators  have  directed  their  efforts  toward 
identifying a differential capacity, either kinetic or in absolute magnitude, in the ability of pathogenic 
and apathogenic hantaviruses to elicit an interferon response in cells. One premise that emerges is that 
apathogenic forms would tend to induce an earlier innate response that would render it more likely that 
the virus would be quickly cleared or rendered less competent in its replication so as to blunt any 
pathological response in the host [40–42]. The anti-hantavirus innate response can in some cases be 
attributed to viral interaction as a ligand of TLR-3, but not in others, and in endothelial cells, it appears 
not to require more than the viral particle itself, even when introduced in replication-incompetent 
form [43,44]. Proteins and mRNAs prominently induced by hantaviruses include MxA and IFIT-1 
(ISG-56) and others including some with known or suspected anti-viral activity. Those hantaviruses, 
often  highly  pathogenic  strains,  that  fail  to  induce  a  potent  antiviral  response,  are  suspected  or 
presumed to have a (more) potent interferon-pathway antagonism mechanism relative to other viruses, 
a mechanism that acts positively to prevent an effective innate response from forming, at least early in Viruses 2010, 2                         
 
 
2564 
infection [42,45]. Yet some instances are reported wherein highly pathogenic hantaviruses, such as 
SNV, are also able to induce expression of interferon-stimulated gene mRNAs, even very early in 
infection, with ISG proteins, as expected, taking longer to appear in the cell [44]. Anti-interferon 
activities have also been attributed to the NSs protein that may be elaborated in cells infected by 
serotypes that encode this protein [46]. Other investigators have examined the activities of hantavirus 
glycoproteins and other proteins that might themselves directly affect some aspects of the pathogenic 
progression associated with hantavirus infection of humans, such as vascular permeability changes. 
While early attempts to directly cause increases in permeability of endothelial monolayers with viral 
particles or viral infection were largely disappointing, hantaviruses have been identified as adversely 
affecting  endothelial  migration  over  substrata  and  in  potentiating  VEG-F-induced  endothelial 
permeability [47,48].  
2.2. The Hantavirus Nucleocapsid Protein 
The  shorter  (50-kD)  nucleocapsid  or  N  protein  is  a  structural  component  of  the  viral 
nucleocapsid,  along  with  the  genomic  viral  RNA  segments.  As  an  RNA-binding  protein  that 
engages  the  hairpin  termini  of  the  genomic  segments  with  high  affinity  [49,50],  it  limits  the 
access of the RNA to host nucleases and helps to render viral replication a closed process within 
the cytoplasm. It also acts as a peripheral membrane protein, as does the L protein [51], an activity 
that could play a role in its presumed, but not yet demonstrated function as matrix [52]. Until recently, 
it had not been appreciated that N has a wide variety of other activities, some of which can be 
linked, not only to fundamental requirements of replication, but also to the interference with an 
array of the intracellular processes of the normal cell. Thus, an interaction between the amino 
terminus of the hantavirus N protein and the cellular protein Daxx has been proposed, with the 
suggestion of potential pro-apoptotic consequences [51]. N is also reported to interact with actin 
microfilaments,  and  the  SUMO-1  protein  [53,54].  Using  reporter-gene  based  assays,  Connie 
Schmaljohn and her colleagues have reported that Hantaan virus’ nucleocapsid protein  has an 
inhibitory  role  in  inflammatory  responses  mediated  by  NF  kappa  B  (NF-B).  The  effects  on 
NF-B  expression  appeared  to  be  confined  to  prevention  of  its  nuclear  translocation  after  its 
attempted  activation  with  lipopolysaccharide,  LPS  [55].  In  the  cytoplasm  of  infected  cells, 
N protein can be found in cellular P bodies where it sequesters and protects 5’ caps. It may locate 
the  caps  through  its  interaction  with  DCP1,  a  key  constituent  of  P  bodies.  During  hantavirus 
infection, the viral RNAs become concentrated in P bodies, through their interaction with N and 
DCP1. The N protein demonstrates preferential protection of mRNAs engineered to prematurely 
terminate their encoded protein in comparison to native mRNAs [56]. 
N  protein  has  been  increasingly  linked  to  viral  replication  and  translation,  sometimes  in 
previously unanticipated ways. It is among a growing family of diverse viral proteins that can 
serve as a nonspecific ―RNA chaperone‖, an activity that should facilitate the L polymerase’s 
access to vRNA for transcription and replication, in that it can transiently dissociate misfolded 
RNA structures [57]. Some of N protein’s effects on translation might not immediately be recognized 
to  be  adaptive  in  nature.  It  can  replace  the  entire  EIF4F  translational  initiation  complex, 
simultaneously presenting the ribosome with a replacement for the cap-binding activity of eIF 4E, Viruses 2010, 2                         
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binding to the 43S pre-initiation complex as does eIF 4G, while replacing the helicase activity of eIF 4A, 
which is presumed to be needed to dissociate higher-order RNA structure [56,58]. These three factors 
normally work together to achieve translational initiation. In P bodies, N protein’s ability to bind at 
high affinity to capped native cellular oligoribonucleotides, along with its activity in protecting 
capped RNAs from degradation likely facilitates the access of capped oligonucleotides for use in 
transcriptional initiation by L polymerase (―cap snatching‖).  
Trafficking  of  N  for  viral  assembly:  Classically,  N  protein  in  infected  cells  appears  to  be 
clustered  or  particulate  in  nature,  with  a  heavy  concentration  at  a  single  perinuclear  location, 
widely considered to be the Golgi [27]. The N proteins of hantaviruses are found in association 
with particulate fractions, and confocal microscopy and biochemical-inhibitor studies have shown 
that N tracks along microtubules but not with actin filaments [52]. The ultimate destination for N, 
for  its  assembly  into  viral  particles  is  the  Golgi,  and  it  traffics  there  via  the  endoplasmic 
reticulum-Golgi  intermediate  complex  (ERGIC),  also  known  as  vesicular-tubular  cluster  [52].  
A dominant negative inhibitor, dynamitin, associated with dynein-mediated transport, reduced N’s 
accumulation  in  the  Golgi.  Later  studies  suggested  that  the  specific  dependence  on  microtubular 
transport is specific to Old World hantaviruses such as HTNV, but that the New World hantavirus 
ANDV is instead associated with actin filaments [59]. However, recent data indicates that microtubular 
transport is indeed utilized for the New World hantavirus SNV [60]. 
3. Pathology and Diagnosis 
Hantavirus diseases of man have long been suspected of having an immunopathogenic basis in part 
because of their relatively long incubation period of 2–3 weeks and the observed temporal association 
between immunologic derangements and the first appearance of signs and symptoms of hantavirus 
illness. HFRS and HCPS share many clinical features, leading many investigators to consider them to 
be, in essence, different manifestations of a similar pathogenic process, differing mainly in the primary 
target organs of disease expression (Table 2). The pathogenesis of hantavirus infections is the topic of 
a continuously-updated review in the series UpToDate [61]. 
By the time symptoms appear in HCPS, both strong antiviral responses, and, for the more virulent 
viral  genotypes,  viral  RNA  can  be  detected  in  blood  plasma  or  nucleated  blood  cells 
respectively [63,64]. At least three studies have correlated plasma viral RNA with disease severity for 
HCPS and HFRS, suggesting that the replication of the virus plays an ongoing and real-time role in 
viral pathogenesis [65–67]. Several hallmark pathologic changes have been identified that occur in 
both HFRS and HCPS. A critical feature of both is a transient (~ 1–5 days) capillary leak involving the 
kidney and retroperitoneal space in HFRS and the lungs in HCPS. The resulting leakage is exudative in 
character, with chemical composition high in protein and resembling plasma. 
3.1. Pathology 
The continued experience indicating the strong tissue tropism for endothelial cells, specifically, is 
among the several factors that make β3 integrin an especially attractive candidate as an important 
in vivo receptor for hantaviruses. It is likely that hantaviruses arrive at their target tissues through 
uptake by regional lymph nodes, perhaps with or within an escorting lung histiocyte. The virus seeds Viruses 2010, 2                         
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local endothelium, where the first few infected cells give rise, ultimately, to a primary viremia, a 
process that appears to take a long time for hantavirus infections [62,63]. 
Table 2. Similarities and differences between HFRS and HCPS. 
  HFRS  HCPS 
Transmission 
Aerosolized wild-rodent excreta, 
no arthropod vector 
Aerosolized wild-rodent excreta, 
no arthropod vector 
Stages 
Incubation period: 1–5 wk, 
prodrome 5–10 d,  
hypotensive phase 1–3 d  
oliguric phage 3–5 d 
convalescence 
Incubation period: 1–5 wk, 
prodrome (febrile phase) 3–10 d, 
cardiorespiratoryphase 1–6 d 
diuretic phase 1–3 d 
convalescence 
Primary organ of attack  Kidney, lymphoreticular system  Lungs, lymphoreticular system 
Location of effusion  Retroperitoneal space 
Thoracic bed; pulmonary 
interstitium 
Pathologic hallmarks 
Capillary leak. Mononuclear 
infiltrate. 
Capillary leak. Interstitial 
mononuclear cell infiltrate. 
Clinical findings 
Fever, chills, nausea and 
vomiting, headache, lethargy, 
oliguria, tachycardia, facial and 
truncal flushing, hemorrhage, 
occasionally noncardiogenic 
pulmonary edema with 
tachypnea, shortness of breath, 
shock, death in 0.1 to 5%. 
Fever, chills, nausea and 
vomiting, headache, lethargy, 
dyspnea, tachycardia, tachypnea, 
shortness of breath, 
noncardiogenic pulmonary edema, 
hemorrhage/petechiae (ANDV), 
shock, death in  
10 to 50%. 
Laboratory findings 
Hypoalbuminemia, azotemia, 
proteinuria, hematuria, 
leukopenia/leukocytosis 
Hypoxia, Hypoalbuminemia, 
thrombocytopenia, 
leukopenia/leukocytosis, 
hemoconcentration  
Treatment 
Specific: ribavirin. Nonspecific: 
cardioventilatory support, 
dialysis 
Specific: none. Nonspecific: 
extracorporeal membrane 
oxygenation (ECMO), 
cardioventilatory support 
 
By the time that secondary viremia emerges, the agents of the more severe forms of HFRS and 
HCPS have begun to achieve sufficient mass as to induce, through PAMP-PRR interactions and other 
means,  the  expression  of  proinflammatory  cytokines  [64].  For  HCPS,  that  expression  favors  the 
pulmonary bed and lymphoid organs, yet, for unknown reasons, spares the retroperitoneum and, in 
general, the kidney. In HFRS the situation is reversed, and yet it is often not appreciated that the 
expected  preferential  tissue  tropism  of  HFRS-associated  viruses  and  their  HCPS-associated 
counterparts for the renal and pulmonary beds, respectively, is not as one would predict through the 
manifestations of the two diseases. 
Local elaboration of inflammatory and chemotactic mediators is considered to be a requirement for 
the development of systemic disease symptoms, with those abnormalities sometimes culminating in 
shock and death. Yet it is not hypoxemia, due to the prominent pulmonary edema, that leads to death in Viruses 2010, 2                         
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most fatal cases of HCPS, but rather intoxication of the heart by as-yet-undefined mediators that leads 
to the low cardiac output state and the associated shock syndrome [64,65]. It is tempting to speculate 
that  mediators  produced  in  the  lung  in  connection  with  the  inflammatory  infiltrate  can  percolate 
through the coronary circulation with minimal dilution in HCPS, a disadvantageous consequence of 
the  close  anatomic  juxtaposition  of  the  two  organs.  Thus,  at  least  three  classes  of  potential 
mechanisms, some overlapping and all certainly nonexclusive of the others, could be presumed to 
underlie the pathogenesis of HCPS. These include:  
(1) Innate immune mechanisms. The nature of interactions between hantavirus pathogen-associated 
molecular patterns (PAMP) with the pattern recognition receptors (PRR) of susceptible endothelial 
cells are beginning to be clarified. The prototypical HTNV appears to be recognized by TLR-3 [43]. 
Such an infection has consequences such as increased expression of HLA-DR in dendritic cells [66] 
and differentiation of monocytes toward dendritic cells [67]. 
(2) Direct viral effects. The observed correlation between viral load and disease severity leaves the 
possibility open that hantavirus particles or RNA can themselves have toxic effects on cells or on 
signaling.  Some  investigators  have  favored  direct  viral  toxicity,  acting  through  the  inhibition  of 
endothelial cell barrier function, as an explanation for much of the capillary leak, although there is 
widespread  agreement  that  multiple  mechanisms  that  mediate  pathogenesis  likely  operate 
simultaneously in the affected patient [68]. A potentially important clue toward the mechanism by 
which  hantavirus  infections  deplete  blood  platelets  and,  in  some  cases  cause  hemorrhagic 
manifestations, was advanced by the recent discovery that pathogenic hantaviruses are able to recruit 
platelets to adhere to endothelial cell surfaces, with β3 integrin used as a critical binding element [69]. 
(3)  Pathogenic  effects  caused  by  the  activities  of  specific  viral  macromolecules.  We  have  
reviewed some of the activities associated with the Gn, Gc and N, virally-encoded polypeptides in 
previous sections. 
Testing models of pathogenesis can be done more effectively when there is an animal model that 
mimics key aspects of the disease. There is no such model that closely mimics HFRS, but animal 
models exist for both the asymptomatic carriage of PUUV and SNV by their native carrier rodents, the 
bank vole Myodes glareolus and the deer mouse P. maniculatus; as well as a Syrian hamster model 
using ANDV or the related Maporal virus from Venezuela, for which an HCPS-mimetic disease is 
observed [70–73]. 
The ANDV-Syrian hamster model has a number of features in common with the human disease, as 
well as some differences. Unlike the neurologic diseases that have been possible to elicit with HTNV, 
the hamster model for HCPS appears to be caused by capillary leak that results in pulmonary edema 
and the production of a pleural effusion with exudative characteristics. Typically the hamsters die 
between 11 and 14-d post-inoculation, reflecting a slightly accelerated incubation period in comparison 
to human infections. As with human HCPS, the microscopic examination of the lung reveals abundant 
fibrin deposition, thickened alveolar septa, and viral antigen expressed abundantly in the microvascular 
endothelium.  ANDV-infected  hamsters  fitted  with  physiologic  monitoring  devices  exhibited 
diminished pulse pressures, tachycardia, and hypotension that appear to closely mimic the shock that is 
believed to be the proximate cause of demise in patients who succumb to HCPS [65,74]. 
Compared to the human disease, ANDV-infected hamsters exhibit exceptionally high titers of live 
ANDV in their tissues, with much of the viral replication occurring in hepatocytes, which are spared in Viruses 2010, 2                         
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the human disease. Titers of live ANDV in some cases exceed 10
8/g, whereas hantavirus isolates from 
human  tissues  have  been  notoriously  difficult  to  obtain.  Despite  the  universal  occurrence  of 
mildly-elevated hepatic enzymes in patients with HCPS, hepatic enzymes do not appear to be present 
at elevated levels in the blood of diseased hamsters even immediately before death [75]. 
3.2. Adaptive Immune Responses 
The protracted incubation period associated with hantavirus disease gives the host considerable 
time to mount a mature immune response against the virus. Thus, in contradistinction to infections of 
comparable  severity  and  related  symptomatology  associated  with  arenaviruses  and  filoviruses, 
hantavirus infections of humans are associated with antibody responses of significant titer by the time 
symptoms  commence.  Despite  this  observation,  it  appears  to  be  possible  that  natural  variation  in 
individual  neutralizing  antibody  responses  among  patients  with  SNV  infections  can  be  linked  to 
disease  severity,  suggesting  that  administration  of  antiviral  antibodies  could  prove  effective 
therapeutically [76]. In the case of ANDV infection, new evidence has emerged indicating that the 
apparent clearance of the virus from the blood does not result in the complete removal of antigenic 
stimulus by the virus, suggesting that the virus may persist, perhaps in some as-yet undetermined 
immunologically privileged site [77]. 
A role for T cell-mediated  pathological responses  in HFRS and  HCPS has  been the source of 
speculation for a variety of reasons. The severity of SNV-associated HCPS may have made it more 
apparent  that  the  onset  of  pulmonary  edema,  tachycardia  and  hypertension  seemed  to  be  all  but 
universally temporally associated with the appearance of a spectrum of highly-activated cells of the 
lymphoid  lineage  in  the  peripheral  blood.  Cells  with  a  close  morphologic  similarity  to  these 
―immunoblasts‖ were detected in the congested, heavy lungs of patients who came to autopsy, as well 
as in lymphoid organs and in the portal triads [63,78–80]. These observations led to speculation that 
some component of hantavirus pathogenesis could be linked to the appearance of antiviral T cells that 
could stimulate or contribute to the appearance of a ―storm‖ of mediators and the associated capillary 
leak phenotype. Subsequent studies have borne out the expectation that a significant fraction of the 
immunoblast  population  in  patients  with  HCPS  are  T  cells  with  specificity  for  specific  class  I 
HLA-presented  epitopes  of  viral  antigens,  including  Gn,  Gc  and  N  [77,81–83].  Presumably,  the 
antiviral  activities  of  such  cells,  manifested  in  part  through  their  elaboration  of  mediators  in  the 
affected  interstitium,  can  contribute  to  the  endothelial/capillary  leak  that  lies  at  the  heart  of 
hantavirus pathogenesis. 
Because early cases of HCPS often came to autopsy, it became possible to examine necropsied 
tissues for expression of cytokines. The study by Mori et al. (1999) revealed high relative expression 
of  proinflammatory  cytokines  including  TNF,  IL-1,  IL-6,  providing  evidence  in  favor  of  a 
―cytokine storm‖  model for pathogenesis  [64]. The authors believed, based on the  morphology  of 
cytokine-secreting cells, that both monocytes and lymphocytes were contributing to the production of 
cytokines.  That  proinflammatory  mediators  are  found  in  elevated  levels  in  the  plasma  as  well  
as the renal interstitium of patients with acute hantaviral illness has been recognized for some time  
as well [84,85]. Viruses 2010, 2                         
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While diagnosis of HCPS as well as HFRS is best accomplished with IgM serology, in the acute 
stage of SNV infection, RT-PCR can also be used if blood cells or blood clot are used instead of 
plasma or serum, where sensitivity even using nested PCR primers drops to about 70% [86–88]. In a 
facility at which many cases of HCPS are treated, the University of New Mexico medical center in 
Albuquerque, a diagnostic service has long been offered in which the patient’s hematologic findings 
are  analyzed  to  establish  the  probability  that  a  patient  has  HCPS.  The  combination  of 
thrombocytopenia, elevated abundance of ―immunoblast‖ lymphocytes, left-shifted polymorphonuclear 
cell population without strong morphologic evidence for their activation, and elevated hemoglobin or 
hematocrit  values  is  highly  specific  for  HCPS  and  allows  clinicians  the  ability  to  put 
presumptive-HCPS patients on extracorporeal membrane oxygenation (ECMO), which is believed to 
have saved many patients from a lethal outcome [89]. 
4. Epidemiology and Epizootiology  
4.1. Epidemiology and Transmission Mechanisms from Rodents to Humans 
Human  infection  by  hantaviruses  is  thought  to  follow  contact  with  secretions  or  excretions 
produced by infected rodents. In the United States, 538 human infections by hantavirus were reported 
through late December 2009 [90], with New Mexico, Arizona and Colorado exhibiting the highest 
case-loads. While the prototypical central American hantavirus in central America was Rio Segundo 
virus of Reithrodontomys mexicanus from Costa Rica, the first human disease appeared some years 
later  in  Panama,  where  Choclo  virus  (CHOV)  arose  as  the  etiologic  agent  and  is  believed  to  be 
responsible for all known cases of HCPS. The fulvous pygmy rice rat Oligoryzomys fulvescens has 
been identified as the rodent reservoir [91]. In Panama, the first cases of HCPS, albeit with little or no 
evident  cardiac  involvement,  were  reported  in  1999,  and  since  then,  106  human  infections  have 
occurred with a 26% mortality rate [92]. Serosurveys of mammals in Mexico and Costa Rica have 
found anti-hantavirus antibodies [93–96], and seroprevalences ranging between 0.6 to 1.6% in human 
populations were reported despite the absence of known HCPS cases [97]. In South America, HCPS 
cases have been indentified in Argentina, Bolivia, Brazil, Chile, Paraguay and Uruguay, and evidence 
for human exposure to hantaviruses have  also been reported in Venezuela [98] and Perú [99]. In 
southern South America, ANDV is the main etiologic agent with cases in Chile and Argentina reported 
since 1995. In Chile, 671 cases of HCPS due to ANDV have occurred during the period 2001–2009 
[100].  Since 1995, more than 1,000 HCPS cases have been reported in Argentina [101];  in Brazil, 
approximately 1,100 HCPS cases have been identified between 1993 and 2008 [102]. Case-fatality ratios 
in those three countries have been similar, ranging from 30% (Argentina), 36% (Chile) and 39% (Brazil). 
Hantavirus infections occur more frequently in men than women, although the male/female ratio is 
highly variable. For example, Panamanian communities showed a ratio of 55 men to 45 women [103], 
while in Chile the ratio is more biased to males (71%) [104]. In the Paraguayan Chaco the male-female 
ratio  approaches  50%  [105].  In  North  America,  by  December  2009  63%  of  case-patients  were  
males  [90].  All  ethnic  and  racial  groups  seem  to  be  susceptible  to  hantavirus  infections,  and  the 
differences between certain groups (as indigenous and non-indigenous) are more likely correlated with 
the type habitat where the population resides (e.g., rural versus urban areas). In fact, rural communities Viruses 2010, 2                         
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account for the highest hantavirus incidences overall and are therefore at higher risk [92,105–111], 
although the importance of peridomestic settings as a major area of exposure has also been emphasized 
[112,113]. 
The main mechanism by which humans acquire hantavirus infection is by exposure to aerosols of 
contaminated rodent feces, urine, and saliva [114,115]. This can occur when humans reside in areas in 
close proximity to those that rodents inhabit, live in areas infested with rodents, or when rodents 
invade human settings, which are more frequent in rural habitats. There is a long history of human 
co-existence with rodents, raising questions about the apparent recent increases in hantavirus-related 
illnesses,  especially  HCPS.  Other  than  an  apparent  association  with  El  Niño  southern  oscillation 
(ENSO) events in some regions [116,117], the recent increases in incidence of HCPS do not seem to 
follow a readily-defined temporal or spatial pattern. However, some landscape features such as habitat 
fragmentation or human-disturbed areas may influence rodent population dynamics and impact viral 
incidence  [118–121].  Despite  the  stochasticity  associated  with  contraction  of  hantavirus  infection, 
certain scenarios have been recognized as posing higher risk. Human activities in poorly ventilated 
buildings that aerosolize particulates that are then inhaled (i.e., cleaning, shaking rugs, dusting) are 
frequently identified among patients admitted for HCPS [11,122]. Outdoor activities are thought to 
convey lower risk due to lability of hantaviruses to UV radiation and the presumed tendency to be 
dispersed in wind, although certain environmental conditions seem to maintain the virus for longer 
periods outside its natural host allowing for indirect transmission [123]. An alternative but uncommon 
route of virus transmission is by rodent bites [124–126]. Field workers handling mammals are potentially 
at higher risk of exposure with hantavirus infections, although when quantified through serosurveys the 
absolute risk appears rather slight [127]. A new study in Colorado suggests the possibility that a rodent 
bite may have been the proximate vehicle for outdoor transmission of SNV [128], which re-emphasizes 
the use of personal protective equipment during field work activities [129]. As a particular case within 
hantaviruses, person-to-person transmission has exclusively been documented for the South American 
Andes  virus  [130–135].  The  identification  of  this  transmission  route  has  been  made  using  both 
molecular tools and epidemiological surveys, but the mechanism of interpersonal transmission is not 
well established. Recent findings show that family clusters and specifically sexual partners share the 
greater risk of interpersonal transmission, although sexual transmission per se can be neither inferred 
nor refuted presently [130,135]. Interestingly, ANDV  may also be shed by humans through other 
biological fluids such as urine [136], illustrating the particular properties that differentiate this virus 
from other hantaviruses. Although interpersonal transmission seems to be unique for ANDV, viral 
RNA of PUUV has been detected in saliva of patients with HFRS, and some patients with SNV-HCPS 
have viral RNA in tracheal secretions [88,137]. 
4.2. Rodent Reservoirs and Cross-species Transmission 
Hantaviruses in the Americas are naturally hosted by rodents (Muridae and Cricetidae) as well as 
shrews (Soricidae) and moles (Talpidae) (Figure 1). Three shrew and one mole species have been 
reported to host hantaviruses and their pathogenicity for humans remains unknown [22,138,139]. At 
least 15 rodent species have been identified as carriers of different pathogenic hantaviruses, with some 
South  American  genotypes  such  as  Castelo  do  Sonhos  (CDSV)  or  Hu39694  only  identified  after Viruses 2010, 2                         
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human infections (Figure 1). Hantaviruses typically show high species-specificity and no intermediate  
host [140]. However, some hantavirus genotypes have been described in the same rodent species. Such 
is the case of Playa de Oro (OROV) and Catacamas (CATV) identified in Oryzomys couesi [141,142], 
or Maporal (MAPV) and Choclo (CHOV) hosted by O. fulvescens [91,143]. In North America both 
Muleshoe and Black Creek Canal hantaviruses have been detected in geographically-distant Sigmodon 
hispidus [144,145]. Also, one hantavirus genotype (e.g., Juquitiba-like virus) may be carried by more 
than  one  rodent  species  (O.  nigripes,  Oxymycterus  judex,  Akodon  montesis).  Another  example  is 
Laguna Negra virus (LANV) which after being identified in Calomys laucha [146] has also been 
reported  in  C.  callosus  [147].  The  rapid  increase  in  the  discovery  of  new  hantaviruses  and  the 
identification  of  their  hosts  does  not  seem  likely  to  end  soon  as  new  small  mammal  species  are 
screened [95]. This subject is complicated by continued controversy in the criteria for the classification 
of distinct hantaviruses [148,149], which is also tied to host taxonomic classification and taxonomic 
rearrangements. 
Cross-species transmission is a major process during spread, emergence, and evolution of RNA 
viruses  [6,150].  Particularly  within  hantaviruses,  spillover  to  secondary  hosts  are  increasingly 
identified as more extensive studies are performed [151–156]. For example, ANDV is the predominant 
etiologic agent of HCPS in South America, and O. longicaudatus the main rodent reservoir. Spillover 
in  at  least  four  other  rodent  species  that  co-occur  with  the  reservoir  have  been  identified,  with 
Abrothrix longipilis showing the second higher prevalence to ANDV-antibodies, and there is presently 
no question that the virus is extremely similar genetically between the two host rodents [157,158]. In 
North  America,  spillover  of  Bayou  virus  (BAYV)  may  have  occurred  from  the  main  reservoir 
O. palustris to S. hispidus, R. fulvescens, P. leucopus, and B. taylori [159–161]. Hantavirus spillover is 
more likely to occur with host populations inhabiting sympatric or syntopic regions [151,162], and 
cross-species transmission would presumably have greater chances of success if the host species are 
closely related [163]. An interesting exception is found between Oxbow virus (OXBV) and Asama 
virus (ASAV) in which a host-switch process seemed to have occurred between mammals belonging to 
two families (Talpidae and Soricidae), likely as a result of alternating and recurrent co-divergence of 
certain taxa through evolutionary time [138]. 
4.3. Outbreaks 
Hantaviruses are horizontally transmitted between rodents and are not transmitted by arthropods 
(unlike other viruses of the family Bunyaviridae). Spillover infection to nonhuman mammals usually 
results in no onward (or ―dead-end‖) transmission, but if humans are infected may result in high 
morbidity and mortality [122,164]. During the spring of 1993, an outbreak of patients with HCPS due 
to SNV occurred in the Four Corners states resulting in more than 60% case-fatality among the initial 
cases, many involving members of the Navajo tribe [12,121]. In Panama, an outbreak was reported 
during 1999–2000 in Los Santos, and 12 cases where identified with three fatalities [165,166]. This 
represented the first report of human hantavirus infections in Central America. In South America, 
the first  largest  identified  outbreak  occurred  in  the  Chaco  region  in  northwestern Paraguay  during 
1995–1996. Seventeen individuals were identified with SNV antibody (ELISA) or were antigen (IHC) 
positive out of 52 suspected cases [167]. Major outbreaks due to ANDV occurred in 1996 in southern Viruses 2010, 2                         
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Argentina  [131,134];  in  southern  Chile  clusters  of  patients  presented  with  hantavirus  illness  
in 1997 [158]. In Brazil, the first outbreak was identified in the Brazilian Amazon (Maranhão State) 
in 2000, and involved small villages that resulted in a 13.3% prevalence of those tested (398 total 
residents) [168]. 
The factors that trigger hantavirus outbreaks are still poorly understood, probably because they 
result from several interacting biotic and abiotic features whose key parameters are difficult to model. 
However, the use of new modeling approaches that involve geographical and environmental features 
seem to be promising in predicting potential hantavirus outbreaks and/or areas of higher risk [169–172]. 
Because hantaviruses are known to be directly transmitted from infected to susceptible hosts, the first 
natural approach is to relate outbreaks to the ecology of the viral hosts. Hantavirus transmission and 
persistence in rodent populations depends on several factors that interact to affect ecological dynamics 
of the host, which in turn is strongly influenced by the behavioral characteristics of individual rodent 
species, to landscape structure, and environmental features [173,174]. Viral transmission depends on 
contact rates among susceptible hosts, and despite the prevailing notion that a higher density increases 
encounters and hence secondary infected hosts, contrasting patterns relating rodent population size and 
virus prevalence can be found [175]. In addition, it has been shown that SNV transmission follows a 
contact  heterogeneity  pattern,  where  individuals  in  the  population  have  different  probability  of 
transmitting  the  infection  [176].  The  understanding  of  viral  transmission  proves  to  be  far  more 
complex when species other than the main reservoir host are incorporated in the model. In fact, recent 
studies have shown that higher hosts species diversity is correlated with lower infection prevalence in 
North America for P. maniculatus [177], in Central America for O. fulvescens (reservoir of Choclo 
virus) and Zygodontomys brevicauda (reservoir of Calabazo virus) [178], and in South America for 
Akodon  montensis  (reservoir  of  Jabora  virus)  [162].  Contact  rates  vary  according  to  the  spatial 
distribution of populations and seem to be strongly influenced by landscape structure. For example, 
SNV prevalence in P. maniculatus was higher in landscapes with a higher level of fragmentation of the 
preferred habitat [179]. In addition, certain properties of the landscape such as elevation, slope, and 
land cover seem to be useful in detecting areas with persistent SNV infections, and therefore thought to 
be  refugial  areas  where  the  virus  can  be  maintained  for  years  [169].  Changes  in  the  natural 
environment of reservoir species, such as forest fragmentation and habitat loss, may alter population 
abundance and distribution and lead to hantavirus outbreaks, as observed in the Azurero Peninsula of 
Panama  [118,119].  Also,  differences  in  the  microhabitat,  including  overstory  cover,  may  lead  to 
differences  in  the  ecological  dynamics  within  populations  and  affect  the  rate  of  exposure  to  the 
virus [180]. Differences in hantavirus infections through contrasting landscapes in the latitudinal span 
have  been  found  in  rodent  populations  of  O.  longicaudatus  in  Chile,  suggesting  that  humans  are 
differentially exposed to the virus [107,181]. 
Rodent population dynamics are affected by seasonal changes of weather and climate [182,183]. In 
the case of the ENSO-associated outbreaks, a complex cascade of events triggered by highly unusual 
rains in the precedent year have been postulated to result in an increase of primary production and 
rodent densities, also increasing the likelihood of transmission of the virus to humans, but it has proved 
difficult to precisely demonstrate the suggested intermediate events such as increased rodent densities 
in the increased caseload [116,121,184]. In South America, effects of climate change and hantavirus 
outbreaks have not been well studied, despite the knowledge that several rodents species that are Viruses 2010, 2                         
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reservoirs of emerging diseases have dramatically been affected by events like El Niño [185]. Changes 
in host population dynamics are also affected by seasonality, which may lead to disease outbreaks 
when processes that equilibrate rodent populations from season to season are interrupted [186].  
Viral emergence may continue to be promoted as human-introduced changes continue to increase in 
the  environment  at  different  geographical  scales.  Human  incursions  into  previously  uncultivated 
environments  may  lead  to  new  contacts  between  rodent  reservoirs  and  humans,  increasing  the 
likelihood of contracting infections [187]. These changes may also alter rodent’s population structure 
and dynamics and interspecies interactions creating conditions that may lead to viral outbreaks, viral 
establishment in new hosts, and emergence of HCPS [102,162], even with seemingly slight ecological 
disturbance to the virus-host system [188].  
5. Concluding Remarks 
Certain  pathophysiologic  characteristics,  including  thrombocytopenia  and  shock,  of  hantavirus 
diseases of humans, bear substantial similarity to the hemorrhagic fevers induced by other viruses such 
arenaviruses,  filoviruses  and  flaviviruses,  despite  sharing  essentially  no  sequence  similarities 
therewith. Such observations raise questions about whether such commonalities in pathogenesis are 
chance similarities of phenotype, or instead report the presence of common molecular mechanisms 
among the viruses. 
In this review we discuss the general properties, discoveries and epidemiology/ecology of the New 
World forms of pathogenic hantaviruses, and also seek to identify some of the characteristics of the 
viral  macromolecules  and  immunologic  mechanisms  that  have  been  proposed  as  potential  direct 
mediators of the pathogenic events that characterize the human disease HCPS. While it is unlikely that 
expression of any particular viral protein or RNAs in isolation can be relied upon to replicate key 
phenotypes of infection by the complete virus, some of the findings have been sufficiently consistent 
with what is known of the pathogenesis in vivo that they offer plausible first-pass leads in the search 
for therapeutic targets. We look forward to the mechanistic revelations that will follow the inevitably 
expanded usage of powerful methods such as deep sequencing, ever-more advanced imaging, and 
microscopic  methods,  and  animal  models  that  can  at  last  be  said  to  be  close  mimics  of  human 
hantavirus disease. 
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